Nucor earnings beat by $0.08, revenue fell short of estimates
Celularity Inc., a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $37.3 million, has been notified by Nasdaq of non-compliance with listing rules due to a delay in filing its annual report. The company, which trades under the ticker CELU for its common stock and CELUW for its warrants, has seen its shares decline over 53% in the past year. According to InvestingPro, the stock currently trades below its Fair Value, though significant risks remain. The company did not meet the deadline for its 2024 Form 10-K report, originally due on March 31, 2025.
The Nasdaq notification, dated April 16, 2025, does not immediately affect Celularity’s listing, allowing trading to continue on the Nasdaq Capital Market. With a concerning current ratio of 0.19 and total debt of $69 million, the company faces significant financial challenges. InvestingPro data reveals multiple warning signs, including rapid cash burn and short-term obligations exceeding liquid assets. Celularity must submit a compliance plan by June 16, 2025. If Nasdaq accepts the plan, the company will have until October 13, 2025, to regain compliance.
Celularity, headquartered in Florham Park, New Jersey, has indicated efforts are underway to file the overdue 2024 Form 10-K promptly. While the company plans to submit a compliance plan within the given timeframe, it acknowledges there is no guarantee of regaining or maintaining compliance.
The potential delisting poses a significant challenge for Celularity, which was previously known as GX Acquisition Corp. before a name change in September 2018. The company’s CEO, Robert J. Hariri, signed the SEC report on April 23, 2025, affirming Celularity’s commitment to addressing the filing delay and working towards meeting Nasdaq’s requirements.
This news is based on a press release statement and reflects the company’s current regulatory standing with Nasdaq. Track Celularity’s financial health metrics and access 8 additional key insights with InvestingPro, your essential tool for monitoring companies facing regulatory challenges.
In other recent news, Celularity Inc. announced its financial maneuvers, including an agreement with YA II PN, Ltd (Yorkville) to extend the maturity date of a $3.15 million convertible note from March 13, 2025, to May 12, 2025. This extension is part of a broader transaction allowing Celularity to sell up to $10 million of its Class A common stock to Yorkville over a 36-month period. Additionally, Celularity entered into a collaboration with BlueSphere Bio, Inc. to manufacture cell therapy products, utilizing its cGMP manufacturing infrastructure for BlueSphere’s T cell receptor therapies. In another development, Celularity amended the exercise price of certain warrants, securing approximately $2.46 million in funding. However, the company faced a setback when it terminated a significant agreement with an institutional investor for the private placement of over 1.2 million shares due to the investor’s failure to provide the subscription amount by the deadline. This termination may affect Celularity’s financial strategy as it seeks alternative funding options. These recent developments highlight Celularity’s ongoing efforts to manage its financial position and expand its operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.